atc market to expand further

so Atripla (TDF/FTC/EFV) is about to be outdone by...

'NewTripla' with Gilead replacing EFV with Tibotec's rilpivrine... as the new blockbuster fixed dose combination pill for hiv...from mid-2011

EFV has always been associated with some bad side effects, which rilpivrine does not have, but both have similar hiv efficacy...

but rilpivrine and 'NewTripla' will have one have one other important difference!

the rate of production of virologic failures with the M184 mutation on NewTripla/rilpivrine will be more than twice that of EFV...

so if 3tc/ftc producing M184, and others producing all those TAMS wasnt enough of a market, NewTripla will now be doing its bit from mid-2011 to expand the ATC market

No other nrti treats M184 and tams, except ATC!

http://www.aidsmeds.com/articles/hiv_rilpivirine_tmc278_1667_18814.shtml